Results 121 to 130 of about 446,044 (333)
Gelatin modified with alkoxysilanes (GelmSi) forms hybrid hydrogels for bioengineering applications
, 2023 Matthieu Simon +8 more
openalex +2 more sources
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Acknowledgment to Reviewers of Bioengineering in 2019
Bioengineering, 2020 Bioengineering Editorial Office
doaj +1 more source
Development of pathological skin models: from conventional techniques to 3D bioprinting
Frontiers in Bioengineering and BiotechnologyReconstructed human skin models were first developed in the 1970s. Since then, they have played a pivotal role in dermatological research, significantly advanced our understanding of skin biology, and brought huge insights into dermatological pathologies.
Maïté Rielland +5 more
doaj +1 more source
Whole-cell Escherichia coli lactate biosensor for monitoring mammalian cell cultures during biopharmaceutical production [PDF]
, 2017 Many high-value added recombinant proteins, such as therapeutic glycoproteins, are produced using mammalian cell cultures. In order to optimise the productivity of these cultures it is important to monitor cellular metabolism, for example the utilisation
Ainsworth, C +5 more
core +1 more source
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Molecular Oncology, EarlyView.Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Bioengineering in women's health: part I [PDF]
, 2019 Kristin S. Miller +2 more
openalex +1 more source
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Production of Living Nanoparticles for Blood Cancer Therapy [PDF]
, 2018 Current cancer therapies leave much to be desired because they are very harmful to the patient and cause a significant decrease in quality of life. Chimeric Antigen Receptors (CAR) are a promising novel approach for treating specific types of leukemia ...
Mitchell, Peter +2 more
core +1 more source